McNeill, C. J., K. U. Sorenmo, et al. (2009). "Evaluation of adjuvant doxorubicin-based chemotherapy for the treatment of feline mammary carcinoma." Journal of Veterinary Internal Medicine 23(1): 123-129.
Mammary carcinoma is the third most common cancer of cats. Female cats with a mean age of 10 to 12 years are primarily affected and approximately 90% of mammary tumors are malignant. Mammary tumors are characterized by local invasion into vasculature and surrounding tissues along with metastasis to distant locations such as draining lymph nodes, lungs, and other sites. A retrospective study was performed to evaluate whether adjuvant doxorubicin-based chemotherapy improved outcomes for cats with mammary carcinoma (MC) compared with surgery alone. Seventy-three cats with naturally occurring, biopsy-confirmed MC were included in the study. The surgery alone group contained 37 cats and 36 cats were in the surgery plus chemotherapy group (adjuvant doxorubicin-based chemotherapy). Median disease free survival and overall survival times were compared between groups. This study did not find a benefit to adjuvant doxorubicin-based chemotherapy in cats with MC. Additional studies are recommended to determine whether certain patients with negative prognostic factors (e.g., tumor size at time of surgical intervention) may benefit from adjuvant chemotherapy. [VT]
>> PubMed Abstract
Related Articles:
Overley, B., F. S. Shofer, et al. (2005). "Association between ovarihysterectomy and feline mammary carcinoma." J Vet Intern Med 19(4): 560-3.
>> PubMed Abstract
Viste, J. R., S. L. Myers, et al. (2002). "Feline mammary adenocarcinoma: tumor size as a prognostic indicator." Can Vet J 43(1): 33-7.
>> PubMed Abstract
More on cat health: Winn Feline Foundation Library
Join us on Facebook
No comments:
Post a Comment